<DOC>
	<DOCNO>NCT02945215</DOCNO>
	<brief_summary>Randomised , double-blind , parallel group study compare PK PD profile IBI301 rituximab patient CD20+ B-cell Lymphoma</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics Safety Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection ( IBI301 ) Compared Rituximab Injection CD20 Positive B Cell Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . CD20positive Bcell lymphoma . 2 . 18 year 65 year . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 4 . Signed informed consent . 5 . Obtained CR ( complete remission ) CRu ( uncertain complete remission ) prior therapy . 1 . Participation another interventional clinical trial past 28 day . 2 . Known allergic reaction monoclonal antibody rituximab . 3 . Rituximab antiCD20 monoclonal antibody use past 4 month . 4 . Blood concentration Rituximab &gt; 24ug/ml . 5 . HIV positive patient . 6 . HCV antigen antibody positive . 7 . Acute chronic hepatitis B virus infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>